Abivax SA (ABVX) Stock Price & How to Invest

Last updated November 2026

Short answer

ABVX is the U.S.-listed ADR of Abivax, a clinical-stage biotech whose value rests almost entirely on obefazimod, an oral drug that delivered positive Phase 3 results in ulcerative colitis in mid-2026 and is headed for a U.S. filing at the end of 2026, so investing here means owning a single-asset, binary regulatory story rather than an established earnings business. As of October 16, 2026 the ADR closed near $89, down about 34% year to date and well off its mid-2026 high near $149, for a market cap around $7.75B.

ABVX stock price

As of 2026-11-16, Abivax SA (ABVX) last closed at $83.61, down 26.4% over the past year. Over the past 52 weeks it has traded between $72.50 and $145.31.

ABVX last close
$83.61
1 day
-4.53%
1 month
-5.13%
1 year
-26.41%
52-week range
$72.50 to $145.31
Last close
2026-11-16

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Abivax SA's investor relations page. Walnut is informational, not investment advice.

ABVX key stats

At $83.61 on November 16, 2026, Abivax SA (ABVX) has a market cap of $7.3B.

Market cap
$7.3B
Price to book
16.2

Market cap, P/E and yield are measured at the $83.61 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Abivax SA (ABVX)?

The last two weeks for Abivax SA, as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • ABVX closed at $83.61 on November 16, 2026, down 3.9% over the past five trading days (from $87.00).

Abivax SA filed no current, quarterly or annual report with the SEC in the last two weeks.

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

What does Abivax SA (ABVX) do?

Abivax SA is a French clinical-stage biopharmaceutical company listed on Nasdaq via a sponsored ADR (ABVX). Its lead and effectively sole value driver is obefazimod (formerly ABX464), a first-in-class oral miR-124 enhancer being developed for inflammatory bowel disease. In 2025 and 2026 the registrational Phase 3 ABTECT program in moderate-to-severe ulcerative colitis reported positive results across both induction trials and the maintenance trial, with the 50 mg dose showing clinical remission around 51% at Week 44 versus roughly 10% for placebo; maintenance results came on June 1, 2026 and Part 2 results with the maintenance safety database on June 29. A pre-NDA interaction with the FDA followed on July 30, management plans to file the U.S. new drug application at the end of 2026, and a Phase 2b Crohn's disease readout (ENHANCE-CD) is expected around mid-2027.

The investment picture is a classic late-stage biotech binary. Abivax has negligible product revenue and posts large ongoing net losses because it is spending heavily on trials and launch preparation, which is normal for a company at this stage and not by itself a red flag. First-half 2026 net loss was EUR 165.9M, including a roughly EUR 43M charge from buying back and cancelling its royalty certificates in May. The shares are highly event-driven: the stock moved from the mid-$90s to the mid-$140s around the mid-2026 Phase 3 data, and an upsized ADS raise at $125 brought in about EUR 767M of net proceeds in early July. Since then the ADR has slid to about $89 as of October 16, 2026, down roughly 34% over three months, while Goldman Sachs initiated at Buy with a $155 target and Wedbush cut its target to $118. Upside depends on FDA approval and a successful launch (or a partnership/acquisition), while the main downside risks are regulatory setbacks, competition, and shareholder dilution.

What's driving Abivax SA (ABVX)?

1. Positive Phase 3 obefazimod data

Both ABTECT induction trials and the maintenance trial met their primary endpoints, with the 50 mg dose reaching roughly 51% clinical remission at Week 44 versus about 10% on placebo. The data positioned obefazimod as a competitive oral option in ulcerative colitis and drove a sharp re-rating of the shares in mid-2026. Abivax is presenting further obefazimod data at United European Gastroenterology Week in October 2026.

2. Path to an FDA filing

After a pre-NDA interaction with the FDA in July 2026, management plans to submit a U.S. new drug application for obefazimod in ulcerative colitis at the end of 2026. Sales and marketing spending has started to rise ahead of a potential U.S. launch. A regulatory filing and any eventual approval would be the key milestones that convert a clinical-stage story into a potential commercial one; no review date exists until the FDA accepts the filing.

3. Pipeline expansion into Crohn's disease

Beyond ulcerative colitis, Abivax is running the Phase 2b ENHANCE-CD induction study of obefazimod in Crohn's disease, with top-line data guided to mid-2027. A second large indication would broaden the addressable market for the same molecule and diversify the single-asset dependence somewhat. A new Chief Medical Officer, Chris Rabbat, takes over from Fabio Cataldi, who leaves in Q4 2026.

4. Strengthened balance sheet

An upsized, oversubscribed U.S. ADS offering priced at $125 in early July 2026 brought in about EUR 767M of net proceeds, on top of EUR 402M of cash and short-term investments at June 30. Management projects the runway into Q4 2029, and the May 2026 repurchase of all royalty certificates for $90M removed a future claim on obefazimod sales. That funding is meant to carry the company through the FDA filing and potential U.S. commercialization without an immediate need to raise again.

What are the risks to Abivax SA (ABVX)?

As a single-asset biotech, essentially all of Abivax's value depends on obefazimod, so a regulatory rejection, a delay, or a negative safety finding could sharply reduce the shares. Malignancy signals at the 50 mg dose have been a focal regulatory question, even though integrated safety data reported rates in line with background disease incidence. The ulcerative colitis market is crowded with established therapies such as Rinvoq, Skyrizi, Zeposia, and Entyvio, so commercial success is not guaranteed even after approval. The company generates negligible revenue and large net losses (about EUR 401M over the trailing twelve months, with spending rising as launch preparation begins), and repeated equity raises have diluted shareholders. The roughly 34% fall in the ADR over three months to October 2026 shows how volatile sentiment remains even after positive data. Approval, launch execution, a leadership transition in the medical function, and any partnership or acquisition outcome all remain uncertain.

What is the Abivax SA (ABVX) forecast?

12 analysts publish price targets on ABVX, averaging $163.58 as of November 2026, or +95.6% against the $83.61 share price on November 16, 2026. The published targets run from $142.00 to $181.00, a narrow spread, and the ratings split 12 buy, 0 hold, 0 sell. Over the last six months there have been 4 raises and 3 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full ABVX forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is ABVX a buy or a sell?

We give no verdict on Abivax SA. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Positive Phase 3 obefazimod data. Both ABTECT induction trials and the maintenance trial met their primary endpoints, with the 50 mg dose reaching roughly 51% clinical remission at Week 44 versus about 10% on placebo. The most optimistic published target, $181.00, assumes this works close to its best case.

The case against. As a single-asset biotech, essentially all of Abivax's value depends on obefazimod, so a regulatory rejection, a delay, or a negative safety finding could sharply reduce the shares. The most pessimistic target, $142.00, is roughly what ABVX is worth if this bites instead.

Read the full bull and bear case on ABVX, including what would have to change to break either one. Walnut is not an investment adviser.

Has Abivax SA (ABVX) split its stock?

No. Abivax SA (ABVX) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is Abivax SA (ABVX) valued?

Market cap, P/E and dividend yield at today's price are in the ABVX key stats above. The business figures below come from Abivax SA's reported results as of October 2026 and change when it next reports.

  • Revenue (TTM): ~negligible (~$4.7M, pre-commercial)
  • Net loss (H1 2026): ~EUR 166M
  • R&D expense (H1 2026): ~EUR 108M
  • Cash and short-term investments: ~EUR 402M (Jun 30, 2026) plus ~EUR 767M net raised in July
  • Cash runway: ~into Q4 2029

As of October 2026: Abivax has effectively no product revenue and posts large net losses, which is normal for a clinical-stage biotech funding late-stage trials and launch preparation rather than a warning sign on its own. Traditional earnings multiples do not apply; the market instead values the probability-weighted potential of obefazimod reaching and selling in the market, and after the 2026 pullback the roughly $7.75B market cap sits well below the average analyst target of about $164 per ADR. The mid-2026 capital raise materially extended the runway and reduced near-term financing risk.

Who competes with Abivax SA (ABVX)?

Oral small-molecule IBD drugs

Obefazimod's most direct competition as an oral therapy comes from JAK inhibitors such as AbbVie's Rinvoq (upadacitinib) and Pfizer's Xeljanz (tofacitinib), plus S1P modulators like Bristol Myers Squibb's Zeposia (ozanimod) and Pfizer's Velsipity. Abivax's pitch is competitive efficacy with a lighter monitoring burden than S1P and JAK options.

Biologic IBD therapies

Injected and infused biologics dominate treatment of moderate-to-severe ulcerative colitis, including AbbVie's Humira and Skyrizi, Takeda's Entyvio, and Johnson & Johnson's Stelara and Tremfya. These set the efficacy and reimbursement benchmarks any new entrant must clear.

Other clinical-stage IBD developers

Numerous biotech and pharma programs are pursuing novel oral and biologic mechanisms for ulcerative colitis and Crohn's disease. As a first-in-class miR-124 enhancer, Abivax differentiates on mechanism, but faces the risk that competing pipeline assets reach the market with comparable or better profiles.

What stocks are similar to Abivax SA (ABVX)?

Other names that sit close to ABVX: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Abivax SA (ABVX)

There are three common ways to get ABVX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so ABVX sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where ABVX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Abivax SA (ABVX)

Abivax is a late-stage, one-drug biotech where the entire investment case hinges on obefazimod reaching the market, funded by a cash runway now projected into Q4 2029 after a large mid-2026 raise, though the shares have given back much of their post-data rally.

More on Abivax SA (ABVX)

Whether ABVX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ABVX a buy or a sell?, and where the stock could go from here in the ABVX stock forecast.

For income investors, whether ABVX pays a dividend and how the payout looks is covered in does ABVX pay a dividend? And to weigh ABVX against a peer, read the full side-by-side comparisons: ABVX vs ABBV and ABVX vs PFE.

Wondering how ABVX fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Abivax SA

Ask Walnut's AI anything about ABVX and see how it fits what you own.

FAQ

What does Abivax (ABVX) do?

+

Abivax is a clinical-stage biopharmaceutical company developing obefazimod, an oral drug for inflammatory bowel disease. It is not yet selling a marketed product, so its value is tied to advancing obefazimod through trials and regulatory review.

Why does ABVX have almost no revenue?

+

Abivax is pre-commercial, meaning its lead drug is not yet approved for sale. Negligible revenue and large net losses (EUR 165.9M in the first half of 2026) are typical for a clinical-stage biotech that is spending heavily on trials and launch preparation rather than generating product sales.

What is obefazimod?

+

Obefazimod (formerly ABX464) is Abivax's lead candidate, a first-in-class oral miR-124 enhancer being developed for ulcerative colitis and Crohn's disease. It is the company's main value driver and the focus of its Phase 3 program.

How did the Phase 3 ulcerative colitis trials go?

+

The Phase 3 ABTECT induction and maintenance trials reported positive results, with the 50 mg dose reaching roughly 51% clinical remission at Week 44 versus about 10% for placebo. The data drove a sharp re-rating of the stock in mid-2026, though the ADR has since fallen back.

When could obefazimod reach the market?

+

Abivax held a pre-NDA interaction with the FDA in July 2026 and plans to file a U.S. new drug application at the end of 2026. Any approval and launch would come later, and timing depends on the FDA review, so the path to commercialization remains uncertain.

Does Abivax have enough cash?

+

At June 30, 2026 Abivax held about EUR 402M in cash and short-term investments, and its early-July ADS offering at $125 added roughly EUR 767M of net proceeds. Management projects the runway into Q4 2029, intended to cover the FDA filing and potential U.S. launch.

Who competes with obefazimod?

+

In ulcerative colitis it would compete with oral drugs like Rinvoq, Xeljanz, Zeposia, and Velsipity, and with biologics such as Humira, Skyrizi, Entyvio, and Stelara. The market is crowded, so commercial success is not guaranteed even after approval.

What are the main risks with ABVX?

+

As a single-asset biotech, its value depends almost entirely on obefazimod, so a regulatory rejection, delay, safety concern, or weak launch could sharply hurt the shares. Repeated equity raises have also diluted shareholders. Walnut is not an investment adviser, and this is for information only.

How did Abivax do in its latest reporting period?

+

Abivax reported first-half 2026 results on September 21, 2026: a net loss of EUR 165.9M versus EUR 100.8M a year earlier, R&D of EUR 107.9M, and a roughly EUR 43M Q2 charge from repurchasing and cancelling its royalty certificates for $90M. The Q2 loss of $1.69 per share was wider than the $0.86 consensus, largely because of that charge.

How has ABVX stock performed in 2026?

+

As of October 16, 2026, ABVX closed near $88.82, down about 34% year to date, 34% over three months and 15% over the past month, after peaking near $149 around the Phase 3 data. Analyst targets range widely, from Wedbush at $118 to Goldman Sachs at $155, with an average near $164. Past moves do not predict future returns.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Abivax SA's investor relations page or your broker before making investment decisions.